- Home
- BNTC
as 02-21-2025 4:00pm EST
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | HAYWARD |
| Market Cap: | 255.9M | IPO Year: | N/A |
| Target Price: | $24.43 | AVG Volume (30 days): | 23.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.54 - $13.29 | Next Earning Date: | 02-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Benitec Biopharma Inc. (BNTC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | BNTC | Director10% Owner | Dec 23 '24 | Buy | $11.12 | 47,520 | $527,174.46 | 7,981,725 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | BNTC | Director10% Owner | Dec 3 '24 | Buy | $9.60 | 42,000 | $403,200.00 | 7,981,725 |
Latest Benitec Biopharma Inc. News
BNTC Breaking Stock News: Dive into BNTC Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
Wall Street Analysts Predict a 127.26% Upside in Benitec Biopharma (BNTC): Here's What You Should Know
GlobeNewswire
8 days ago
Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update
GlobeNewswire
8 days ago
Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association Clinical and Scientific Conference
GlobeNewswire
a month ago
Benitec Biopharma to Participate in Upcoming Conferences in January and February
Zacks
a month ago
Why You Shouldn't Bet Against Benitec Biopharma (BNTC) Stock
Simply Wall St.
2 months ago
Hedge funds investors own a significant stake of 38% in Benitec Biopharma Inc. (NASDAQ:BNTC)
TipRanks
2 months ago
Benitec Biopharma initiated with a Buy at H.C. Wainwright
MT Newswires
2 months ago
HC Wainwright Initiates Benitec Biopharma at Buy With $28 Price Target
Compare BNTC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BNTC Benitec Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.